JP2017505756A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505756A5
JP2017505756A5 JP2016538663A JP2016538663A JP2017505756A5 JP 2017505756 A5 JP2017505756 A5 JP 2017505756A5 JP 2016538663 A JP2016538663 A JP 2016538663A JP 2016538663 A JP2016538663 A JP 2016538663A JP 2017505756 A5 JP2017505756 A5 JP 2017505756A5
Authority
JP
Japan
Prior art keywords
antigen
tau species
binding portion
isolated antibody
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/069967 external-priority patent/WO2015089375A1/en
Publication of JP2017505756A publication Critical patent/JP2017505756A/ja
Publication of JP2017505756A5 publication Critical patent/JP2017505756A5/ja
Pending legal-status Critical Current

Links

JP2016538663A 2013-12-13 2014-12-12 可溶性高分子量（ｈｍｗ）タウ種およびその用途 Pending JP2017505756A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361915762P 2013-12-13 2013-12-13
US61/915,762 2013-12-13
US201462030984P 2014-07-30 2014-07-30
US62/030,984 2014-07-30
US201462045313P 2014-09-03 2014-09-03
US62/045,313 2014-09-03
PCT/US2014/069967 WO2015089375A1 (en) 2013-12-13 2014-12-12 Soluble high molecular weight (hmw) tau species and applications thereof

Publications (2)

Publication Number Publication Date
JP2017505756A JP2017505756A (ja) 2017-02-23
JP2017505756A5 true JP2017505756A5 (enExample) 2018-01-25

Family

ID=53371862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538663A Pending JP2017505756A (ja) 2013-12-13 2014-12-12 可溶性高分子量（ｈｍｗ）タウ種およびその用途

Country Status (5)

Country Link
US (2) US20160333063A1 (enExample)
EP (1) EP3080611B1 (enExample)
JP (1) JP2017505756A (enExample)
CN (1) CN106030310B (enExample)
WO (1) WO2015089375A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494877B1 (en) * 2017-12-11 2024-02-07 Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen Device for the examination of neurons
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3548616A4 (en) 2016-12-01 2020-05-13 Sangamo Therapeutics, Inc. TAU MODULATORS AND METHODS AND COMPOSITIONS FOR THEIR ADMINISTRATION
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN113226333A (zh) 2018-10-02 2021-08-06 桑格摩生物治疗股份有限公司 用于调控Tau蛋白的方法和组合物
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
US20230088509A1 (en) * 2020-05-20 2023-03-23 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
WO2024094597A1 (en) * 2022-10-31 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) Method of preparation of amyloidogenic protein aggregates and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5580748A (en) 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20030170678A1 (en) 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
JP2006502748A (ja) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
EP1545582A4 (en) * 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP2369348A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
US7771937B2 (en) 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
GB0605337D0 (en) * 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
MX2009001937A (es) 2006-08-21 2009-04-30 Novartis Ag Biomarcadores para el progreso de la enfermedad de alzheimer.
US20080318220A1 (en) 2007-06-20 2008-12-25 Fina Biotech, S.L. Method for the diagnosis and/or prognosis of alzheimer's disease
WO2009009457A1 (en) 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
WO2009033151A1 (en) * 2007-09-07 2009-03-12 The Trustees Of Columbia University In The City Of New York Tau protein screening assay
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US20110312059A1 (en) * 2008-08-20 2011-12-22 Oligomerix Inc. Tau protease compositions and methods
WO2010048497A1 (en) 2008-10-24 2010-04-29 Genizon Biosciences Inc. Genetic profile of the markers associated with alzheimer's disease
KR20100080068A (ko) 2008-12-31 2010-07-08 주식회사 툴젠 신규한 징크 핑거 뉴클레아제 및 이의 용도
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
AU2010286501B2 (en) * 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
NO2510096T3 (enExample) 2009-12-10 2015-03-21
WO2012144972A2 (en) 2010-01-19 2012-10-26 The General Hospital Corporation Methods to inhibit neurodegeneration
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
WO2013103964A1 (en) * 2012-01-06 2013-07-11 Gencia Corporation Methods and compositions for treating proteinopathies
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP2016507244A (ja) 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集

Similar Documents

Publication Publication Date Title
JP2014132019A5 (enExample)
WO2017087589A3 (en) Pd1 and/or lag3 binders
WO2018226580A3 (en) ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR METHODS OF USE
WO2015127405A3 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
EP4324518A3 (en) Antibody molecules to tim-3 and uses thereof
JP2017176174A5 (enExample)
CN109790222A (zh) 抗密蛋白18a2的抗体及其应用
WO2015156870A3 (en) Biopolymer-mediated assembly of nanoparticles using genetically encoded proteins
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2015157629A3 (en) Antibodies, pharmaceutical compositions and uses thereof
CN110520441B8 (zh) 抗TGF-β抗体及其用途
HK1254952A1 (zh) Ctla4结合剂
MY198240A (en) Compositions and methods related to scavanger particles priority claim
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
AR105267A1 (es) Anticuerpos de unión a tau
MX2016000381A (es) Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1.
WO2016032949A8 (en) Targeting immunotherapy for amyloidosis
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
JP2018520946A5 (enExample)
WO2017083515A3 (en) Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof